AmplideX Fragile X Dx & Carrier Screen Kit

AmplideX Fragile X Dx & Carrier Screen Kit is a PCR-based test from Asuragen (now part of Bio-Techne) that sizes the CGG repeat expansion in the FMR1 gene — the genetic defect that causes Fragile X syndrome, the most common inherited form of intellectual disability. The mechanism is well understood: when the CGG tract expands past ~200 repeats, the FMR1 promoter becomes hypermethylated and the gene is transcriptionally silenced. Loss of its protein product, FMRP — a translational regulator that brakes synaptic protein synthesis — disinhibits protein production at neuronal synapses, producing the intellectual disability, autism features, and anxiety profile of Fragile X. From a single blood draw, the kit categorizes patients as normal, premutation carrier (55–200 repeats), or full mutation (>200 repeats), replacing the multi-day Southern blot workflow that was the diagnostic standard for decades. Clinicians use it to confirm Fragile X in symptomatic children, screen prospective parents for carrier status, and assess premutation-associated risks like Fragile X-associated tremor/ataxia syndrome (FXTAS) and primary ovarian insufficiency (FXPOI). [1][2][3]

The kit received FDA De Novo authorization under DEN190023 — a key distinction from a 510(k) clearance, because the De Novo pathway creates a new device category when no predicate exists, and later Fragile X kits would clear against AmplideX as the predicate. [3] It is commercially available today as an IVD (in vitro diagnostic — a regulated test kit sold for clinical use) sold to clinical laboratories worldwide; physicians don't order it directly, they order Fragile X testing from a reference or hospital lab that has validated and adopted the kit. Major reference labs and academic centers run it as one option alongside laboratory-developed Southern blot or alternative PCR workflows. CMS reimburses Fragile X analysis under CPT codes 81243 (full gene analysis) and 81244 (characterization of alleles), with clinical laboratory fee schedule payments roughly in the $250–$350 range depending on which code is billed. Coverage is generally available when there is documented clinical indication: intellectual disability or autism workup with family history, reproductive carrier screening, fertility workup for premature ovarian insufficiency, or FXTAS evaluation in older premutation carriers. Bio-Techne acquired Asuragen in 2021 for approximately $215M up-front plus earnouts, folding the AmplideX franchise into its diagnostics segment. [4]

The chemistry is repeat-primed PCR (RP-PCR), the technical workaround for a problem that broke standard PCR: when CGG repeats run into the hundreds or thousands, normal primers cannot amplify across the repeat tract. RP-PCR uses a chimeric primer that binds inside the CGG repeat itself, producing a stuttered ladder of products that lets the instrument read out repeat length even into the full-mutation range (>200 repeats). [1] One reaction calls normal alleles (~5–44 repeats), intermediate (45–54), premutation (55–200), and full mutation (>200), and resolves AGG interruptions in the repeat tract — those AGGs matter because they stabilize the repeat against expansion during female meiosis, so a premutation carrier with multiple AGGs has a lower risk of having a child with a full mutation than one without. [2] Sample is EDTA whole blood; DNA extraction is standard; readout is capillary electrophoresis (a technique that sorts DNA fragments by size as they migrate through a thin capillary under voltage). The core technical claim is that one PCR workflow replaces the Southern blot plus PCR combination that labs historically ran in parallel to cover both normal-range sizing and full-mutation detection. critically, however, PCR sizes the repeat but does not determine methylation status; some labs retain Southern blot as a reflex specifically for full-mutation samples where methylation state would change clinical interpretation — for example, in males where an unmethylated full mutation can produce a milder phenotype than a fully methylated one. Validation studies reported concordance with Southern blot in the >99% range across thousands of samples, including the difficult cases: mosaic alleles, low-abundance expanded alleles in maternal samples, and methylation-status interpretation in females where X-inactivation skewing (preferential silencing of one X chromosome over the other) complicates direct PCR readouts. Very large expansions in the multi-thousand-repeat range remain technically harder to size precisely by RP-PCR than mid-range full mutations, though categorical classification (full mutation vs. premutation) is robust. [1][2] The kit's label covers whole blood; prenatal samples (chorionic villus sampling, amniocentesis) fall outside the IVD-authorized indication and are typically run as a laboratory-developed validation by individual labs.

Analytical performance was established across multiple peer-reviewed validation studies. Filipovic-Sadic et al. (Clinical Chemistry, 2010) reported on the original AmplideX method against several hundred samples spanning the normal-to-full-mutation range, with high concordance to Southern blot reference. [1] Yrigollen et al. (Genetics in Medicine, 2017) characterized AGG interruption detection performance and its impact on premutation expansion risk estimates — work that anchors the AGG-resolution claim of the kit. [2] The De Novo submission included a multi-center analytical validation; the FDA decision summary describes performance across thousands of samples with high concordance (>99%) to comparator methods, which is the basis for both the structured sensitivity and specificity values reported here. [3] These figures are analytical concordance against Southern blot as the reference method, not clinical sensitivity/specificity against disease truth. Clinical utility — meaning does running this test change patient management — rests on underlying medical practice rather than on kit-specific outcomes studies. ACMG and ACOG both recommend FMR1 analysis in defined clinical scenarios: developmental delay or intellectual disability workup, autism with positive family history, reproductive carrier screening, FXPOI or early menopause workup, and FXTAS evaluation in older premutation carriers. [5][6] The diagnostic answer drives reproductive decisions, prenatal testing recommendations for premutation carrier women, and genetic counseling. But there is no disease-modifying therapy for Fragile X syndrome itself, so the test informs family planning and supportive care rather than directing treatment. That is the honest framing of the value: high-stakes information with limited therapeutic actionability today.

Fragile X testing is a mature, multi-vendor market. Laboratory-developed tests (LDTs — assays designed, validated, and run by a single clinical laboratory rather than sold as kits) at major US reference labs (Quest, LabCorp, ARUP, Mayo) historically dominated the workflow, often combining a PCR screen with reflex Southern blot for positives. AmplideX competes by offering an IVD-authorized single-workflow alternative — relevant for hospital labs and international markets where regulatory status matters more than for a US LDT. Abbott, Promega, and other vendors sell FMR1 PCR reagents, but the De Novo authorization gives AmplideX a regulatory moat for kits marketed in the US as IVDs. [3] Specific kit revenue is not broken out in Bio-Techne financial reporting; the diagnostics franchise is reported in aggregate within a broader corporate revenue base of roughly $1.1B–$1.2B annually, with segment-level trajectory post-Asuragen disclosed only at the diagnostics-and-genomics segment level rather than per platform. [7] The AmplideX platform has been extended beyond Fragile X to other repeat-expansion and copy-number disorders, including SMN1 and SMN2 (spinal muscular atrophy carrier screening and confirmation) and C9orf72 (ALS/FTD), using the same RP-PCR chemistry. The strategic value to Bio-Techne is less about Fragile X kit revenue and more about owning the RP-PCR franchise as a platform across genetic disorders driven by repeat expansions, where Southern blot is the legacy method and a PCR-only workflow is the upgrade.

Clinically meaningful within a narrow remit: confirm or rule out an FMR1 expansion, support carrier screening, inform genetic counseling. The kit itself is solid technology that solved a real lab workflow problem — eliminating Southern blot for full-mutation sizing is a legitimate improvement, not marketing, with the residual caveat that methylation-sensitive cases still drive some labs back to Southern blot. The adoption ceiling is set by underlying clinical demand for Fragile X testing, which is steady but not growing rapidly. Full-mutation Fragile X syndrome affects approximately 1 in 4,000 males and 1 in 8,000 females; premutation carrier frequency is roughly 1 in 150–200 females, the population that actually drives the reproductive carrier screening market. [6] Carrier screening is recommended but not universally adopted (ACOG endorses it for women with family history or reproductive concerns, short of population-wide). [6] What would change the curve: (1) approval of a disease-modifying therapy for Fragile X — several mGluR5 (metabotropic glutamate receptor 5, a synaptic signaling target implicated in FXS) modulators failed Phase 3 in the 2010s (Roche's mavoglurant, Novartis's basimglurant), and current efforts focus on FMR1 reactivation and ASO (antisense oligonucleotide — short synthetic nucleic acids that bind RNA to alter splicing or expression) approaches, none yet FDA-approved. Specific watchable programs include the QurAlis ASO program licensed from UMass Chan/Quiver targeting FMR1 mis-splicing (preclinical/early translational as of 2026), FRAXA Research Foundation-funded ASO validation work, and academic EZH2-inhibition reactivation efforts (still preclinical); investors should treat these as early-stage with multi-year horizons rather than near-term catalysts. [8] (2) expansion of the AmplideX platform into higher-volume indications like SMA carrier screening, materially larger than Fragile X because every US state now mandates SMA newborn screening on the RUSP panel and Spinraza/Zolgensma/Evrysdi launches drove confirmatory testing volume — exact comparative market sizing is not publicly broken out by Bio-Techne; (3) shifts in payer coverage toward routine reproductive carrier screening panels that include FMR1 by default. Check back when Bio-Techne breaks out AmplideX platform revenue separately, when a Fragile X therapeutic enters Phase 2/3 with positive readouts, or when ACOG updates carrier screening guidance to recommend universal FMR1 screening.